Copyright © 1994 by the European Society of Cardiology.
© 1994 The European Society of Cardiology
The clinical course of heart failure and its modificafion by ACE inhibitors: insights from recent clinical trials
Department of Medicine (Cardiology) Hammersmith Hospital, Du Cane Road, London W12 0HS, U.K.
Received 6 January 1993; revised 7 September 1993; .
Correspondence: J G. F. Cleland, Department of Medicine (Cardiology), Hammersmith Hospital, Du Cane Road, London W12 0HS, U.K.
Abstract
Our understanding of the clinical course of heart failure and the mechanism by which ACE inhibitors reduce mortality and morbidity is being enhanced by recent results from large trials. The belief that heart failure constitutes a gradual progression of symptoms and signs leading eventually to death has been challenged by the finding that many patients die suddenly, before the onset of symptoms at rest. Indeed, many studies have shown that sudden death, with or without the progression of heart failure, is the most common mode of death.
Studies suggest that ACE inhibitors reduce mortality in heart failure both by preventing or delaying the progression of heart failure or sudden death, and by reducing the incidence of myocardial infarction. ACE inhibitors may improve ventricular function by a variety of mechanisms, including effects on neuro-endocrine systems, haemodynamic effects, and direct actions on the myocardium. ACE inhibitors may also have a long-term effect on plaque growth or rupture, which may account for the observed reduction in the incidence of myocardial infarction. Although ACE inhibitors would be expected to lower the risk of arrlhythmias, through their ability to reduce pressure and volume overload, this effect has not been observed consistently in large- scale trials.
One of the most important clinical benefits of ACE inhibition may prove to be the reduction in myocardial infarction. The use of an ACE inhibitor should be considered in all patients with significantly impaired systolic left ventricular function (in the absence of contra- indications), even those who are asymptomatic, although the precise level of ventricular dysfunction at which treatment should be initiated remains to be clarified. The ability of long-term ACE inhibitor treatment to reduce ischaemic events in patients with normal left ventricular function is currently being studied. The optimum dose remains to be determined, although beneficial results have been obtained with enalapril, 20 mg daily, captopril, 150 mg daily and ramipril 5 mg b.i.d.
Key Words: Heart failure • clinical trials • ACE inhibitors
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P A Poole-Wilson, B F Uretsky, K Thygesen, J G F Cleland, B M Massie, and L Ryden Mode of death in heart failure: findings from the ATLAS trial Heart, January 1, 2003; 89(1): 42 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W Ruzyllo, L Chojnowska, M Demkow, A Witkowski, B Kusmierczyk-Droszcz, W Piotrowski, L Rausinska, M Karcz, L Malecka, and W Rydlewska-Sadowska Left ventricular outflow tract gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardiomyopathy Eur. Heart J., May 1, 2000; 21(9): 770 - 777. [Abstract] [PDF]
|
|
|
|
|
|
L Faber, A Meissner, P Ziemssen, and H Seggewiss Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients Heart, March 1, 2000; 83(3): 326 - 331. [Abstract] [Full Text]
|
|
|
|
|
|
F.H. Gietzen, Ch.J. Leuner, U. Raute-Kreinsen, A. Dellmann, J. Hegselmann, C. Strunk-Mueller, and H.J. Kuhn Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy Eur. Heart J., September 2, 1999; 20(18): 1342 - 1354. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Kawahira, Y. Sawa, M. Nishimura, S. Sakakida, H. Ueda, Y. Kaneda, and H. Matsuda GENE TRANSFECTION OF BETA 2-ADRENERGIC RECEPTOR INTO THE NORMAL RAT HEART ENHANCES CARDIAC RESPONSE TO BETA-ADRENERGIC AGONIST J. Thorac. Cardiovasc. Surg., September 1, 1999; 118(3): 446 - 451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The Study Group on Diagnosis of the Working Group Increasing awareness and improving the management of heart failure in Europe: the IMPROVEMENT of HF initiative Eur J Heart Fail, June 1, 1999; 1(2): 139 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Faber, H. Seggewiss, and U. Gleichmann Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy : Results With Respect to Intraprocedural Myocardial Contrast Echocardiography Circulation, December 1, 1998; 98(22): 2415 - 2421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Lakkis, S. F. Nagueh, N. S. Kleiman, D. Killip, Z.-X. He, M. S. Verani, R. Roberts, and W. H. Spencer III Echocardiography-Guided Ethanol Septal Reduction for Hypertrophic Obstructive Cardiomyopathy Circulation, October 27, 1998; 98(17): 1750 - 1755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Braunwald Induced Septal Infarction : A New Therapeutic Strategy for Hypertrophic Obstructive Cardiomyopathy Circulation, April 15, 1997; 95(8): 1981 - 1982. [Full Text]
|
|
|
|
|
|
C. Knight, A. S. Kurbaan, H. Seggewiss, M. Henein, M. Gunning, D. Harrington, D. Fassbender, U. Gleichmann, and U. Sigwart Nonsurgical Septal Reduction for Hypertrophic Obstructive Cardiomyopathy : Outcome in the First Series of Patients Circulation, April 15, 1997; 95(8): 2075 - 2081. [Abstract] [Full Text]
|
|